News
The country isn’t getting extra money from the Global Fund to Fight Aids, TB and Malaria; it has to use cash from a grant it ...
Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...
A new twice-yearly shot could be a "game changer" in the fight against AIDS, but experts' hopes have dimmed because of the ...
GSK expands Medicines Patent Pool deal to allow generic production of cabotegravir for HIV treatment
GSK has expanded its voluntary licensing agreement with the United Nations-backed Medicines Patent Pool (MPP) for cabotegravir, allowing it to be produced by three generic drugmakers and supplied to ...
Global deaths from AIDS have dropped to their lowest levels in more than 30 years, in part due to efforts to fight HIV. But US funding cuts could soon reverse that progress, experts warn.
19h
Zacks Investment Research on MSNMerck Starts Phase III Studies on Once-Monthly Pill for HIV PreventionMerck MRK recently launched two late-stage clinical studies to evaluate MK-8527, its investigational once-monthly oral pill for HIV pre-exposure prophylaxis (PrEP). The EXPrESSIVE-11 study, which ...
Cabenuva is administered every two months and was offered to patients who achieved viral suppression from daily treatments.
Gilead Sciences, Inc. (NASDAQ:GILD) is one of Goldman Sachs’ top healthcare stock picks. On July 10, the company announced it ...
HIV pharma leaders are at Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results